Absolute risk low, but findings may help inform treatment decisions, say researchers Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ today. Although the absolute ...
Use of newer GLP-1 receptor agonists for obesity or diabetes was associated with a reduction in hospital admissions suggesting a potential role for the treatment of alcohol-use disorder Use of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes by people with alcohol-use disorder was associated with a ...
Treatment decisions should be individualised, balancing expected benefits, harms, treatment burden, costs, availability, and patient preferences, say researchers Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life and few show cardiovascular benefits at one year, finds an analysis of the latest evidence published ...
Odds of ischaemic optic neuropathy nearly 5 times higher than among users of Ozempic And 3 times higher in men than in women, analysis of unintended side effect reports shows Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ‘eye stroke’ (ischaemic optic neuropathy) and sudden ...
Findings suggest a potential role in both prevention and treatment of various substance use disorders, say researchers Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity may also help to lower the risk of addiction to a range of substances including alcohol, cannabis, cocaine, nicotine, and ...
Weekend catch-ups linked to heightened risk of insulin resistance in those sleeping more Sleeping for 7 hours and 18 minutes every night may be the sweet spot for warding off the risk of insulin resistance—the precursor to type 2 diabetes—suggests a large observational study published in the open access journal BMJ ...
The BMJ research: sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases In October 2025, The BMJ published the first nationwide population based cohort study to examine the association between sodium-glucose cotransporter-2 (SGLT2) inhibitors and risk of autoimmune rheumatic diseases (ARDs). Drawing on data from more than ...
Copyright © 2026 BMJ Publishing Group Limited. All rights reserved.
Cookie settings | Accessibility | Cookie policy | Modern Slavery Statement | Privacy policy | Website terms and conditions
